Perspective Therapeutics Inc (CATX) 뉴스

Form 8-K - Current report

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the...

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”...

Form 8-K - Current report

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody...

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results

SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”...

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”...

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”...